Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT
- 1 October 2021
- journal article
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- Vol. 8 (17), 1-90
- https://doi.org/10.3310/eme08170
Abstract
Efficacy and Mechanism Evaluation Volume: 8, Issue: 17, Published in October 2021Keywords
Funding Information
- Efficacy and Mechanism Evaluation Programme (14/02/17)
- Medical Research Council
This publication has 19 references indexed in Scilit:
- Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infectionLiver International, 2016
- Adherence to treatment of chronic hepatitis CMedicine, 2016
- HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvirJournal of Hepatology, 2016
- Global distribution and prevalence of hepatitis C virus genotypesJournal of Hepatology, 2014
- Hepatitis C can be cured globally, but at what cost?Science, 2014
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1The New England Journal of Medicine, 2014
- Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C TherapiesGastroenterology, 2013
- Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the futureJournal of Hepatology, 2011
- The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1aJournal of Medical Virology, 1999
- Discriminant validity of the Medical Outcomes Study cognitive function scale in HIV disease patientsQuality of Life Research, 1998